R J Fontana

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 18:1053-9. 2012
  2. ncbi YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Liver Int 32:665-74. 2012
  3. ncbi Assessment of the newly diagnosed patient with chronic hepatitis B virus infection
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Am J Med 121:S22-32. 2008
  4. ncbi Acute liver failure including acetaminophen overdose
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Med Clin North Am 92:761-94, viii. 2008
  5. ncbi Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
  6. ncbi Approaches to the study of drug-induced liver injury
    R J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Pharmacol Ther 88:416-9. 2010
  7. ncbi Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48103, USA
    Hepatology 52:730-42. 2010
  8. ncbi Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 7:219-26. 2009
  9. ncbi Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Am J Gastroenterol 105:1551-60. 2010
  10. ncbi Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 138:2321-31, 2331.e1-2. 2010

Detail Information

Publications106 found, 100 shown here

  1. ncbi Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 18:1053-9. 2012
    ....
  2. ncbi YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Liver Int 32:665-74. 2012
    ....
  3. ncbi Assessment of the newly diagnosed patient with chronic hepatitis B virus infection
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Am J Med 121:S22-32. 2008
    ....
  4. ncbi Acute liver failure including acetaminophen overdose
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Med Clin North Am 92:761-94, viii. 2008
    ..One-year survival after emergency liver transplantation is 70%, but 20% of listed patients die, highlighting the importance of early referral of patients who have ALF with a poor prognosis to a transplant center...
  5. ncbi Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
    ..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)...
  6. ncbi Approaches to the study of drug-induced liver injury
    R J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Pharmacol Ther 88:416-9. 2010
    ..This would facilitate further research into the pathogenesis of DILI, leading ultimately to the prevention of this condition...
  7. ncbi Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48103, USA
    Hepatology 52:730-42. 2010
    ..These networks should also collect biological samples that may provide crucial insights into the mechanism(s) of DILI with the ultimate aim of preventing future cases of DILI...
  8. ncbi Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 7:219-26. 2009
    ..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined...
  9. ncbi Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Am J Gastroenterol 105:1551-60. 2010
    ....
  10. ncbi Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 138:2321-31, 2331.e1-2. 2010
    ..We aimed to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis...
  11. ncbi Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Drug Saf 32:55-68. 2009
    ..Drug-induced liver injury (DILI) is an uncommon adverse drug reaction of increasing importance to the medical community, pharmaceutical industry, regulatory agencies and the general public...
  12. ncbi Acute liver failure due to drugs
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Semin Liver Dis 28:175-87. 2008
    ..Investigation of host variability in metabolic, regeneration, and immunological pathways may provide insights into the molecular basis of DILI as well as improved diagnostic and prognostic biomarkers...
  13. ncbi Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Am J Gastroenterol 106:884-93. 2011
    ..The objective of this study was to determine the incidence and risk factors associated with new-onset and worsening portal hypertensive gastropathy (PHG) in patients with chronic hepatitis C (CHC)...
  14. ncbi A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report
    Fawwaz Humayun
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    J Med Case Reports 1:88. 2007
    ..Two randomized controlled trials of bupropion therapy for smoking cessation did not report any hepatic adverse events. However, there are three reports of severe but non-fatal bupropion hepatotoxicity published in the literature...
  15. ncbi Side effects of long-term oral antiviral therapy for hepatitis B
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    Hepatology 49:S185-95. 2009
    ..Studies on the safety of long-term therapy with the nucleoside analogs, alone and in combination, are needed as are further studies of children, the elderly, pregnant women, and patients with renal insufficiency...
  16. ncbi Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:1154-63. 2007
    ....
  17. ncbi Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave, St Louis, MO 63110, USA
    N Engl J Med 359:2429-41. 2008
    ..Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain...
  18. ncbi Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients
    A S Rangnekar
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Aliment Pharmacol Ther 36:104-14. 2012
    ..Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin...
  19. ncbi Hepatitis B infection in patients with acute liver failure in the United States
    E K Teo
    University of Michigan Medical Center, Ann Arbor 48109, USA
    Hepatology 33:972-6. 2001
    ..Contrary to earlier reports, occult HBV infection was not present in this large series of ALF patients in the United States. HBV precore and/or core promoter variants were common among US patients with ALF caused by hepatitis B...
  20. ncbi Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis
    A K Singal
    Division of Gastroenterology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
    Aliment Pharmacol Ther 35:674-89. 2012
    ..The optimal oral anti-viral agent to use in patients with decompensated HBV cirrhosis remains unclear...
  21. ncbi A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation
    R J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 7:504-10. 2001
    ....
  22. ncbi DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    J Hepatol 49:548-56. 2008
    ..As part of the HALT-C trial we evaluated genetic associations among patients infected with HCV genotype 1 who had failed previous interferon treatment...
  23. ncbi The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis
    Arun J Sanyal
    Division of Gastroenterology, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Gastrointest Endosc 64:855-64. 2006
    ..758). CONCLUSIONS: The risk of having varices increases with decreasing platelet counts, increasing bilirubin, and INR. The probability of having medium or large varices at platelet counts >150,000/mm(3) is negligible in this population...
  24. ncbi Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Gastroenterol 103:2766-75. 2008
    ..The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin...
  25. ncbi Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence
    Pratima Sharma
    University of Michigan Health Systems, Division of Gastroenterology and Department of Pathology, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:1100-8. 2007
    ..Similar to non-LT patients, those with lower pretreatment HCV RNA, a week 12 virological response, and pegylated IFN and RBV dose adherence were more likely to achieve SVR...
  26. ncbi Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine and the Consortium for Health Outcomes Innovation and Cost Effectiveness Studies, University of Michigan Medical School, Ann Arbor, MI 48109 0362, USA
    Psychosomatics 43:378-85. 2002
    ..Because of its brevity and simplicity, the Brief Symptom Inventory may prove to be a useful adjunct to clinician assessment in detecting and monitoring emotional distress during interferon-alpha treatment of chronic hepatitis C...
  27. ncbi Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Liver Transpl 8:433-9. 2002
    ....
  28. ncbi Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial
    Robert J Fontana
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 101:983-92. 2006
    ..The clinical relevance of these findings will be further explored during the randomized phase of the HALT-C study...
  29. ncbi Outcome of liver transplantation for hepatitis B: report of a single center's experience
    C J Chu
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Liver Transpl 7:724-31. 2001
    ..Among patients with no virological breakthrough, lamivudine can stabilize or improve liver disease for up to 4 years in patients with recurrent hepatitis B post-LT...
  30. ncbi Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C
    R J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Mich, USA
    Dig Dis 18:107-16. 2000
    ..Recognition and management of the neuropsychiatric side effects of antiviral therapy will be of growing clinical importance as additional patients with chronic hepatitis C are treated and longer durations of therapy are utilized...
  31. ncbi Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C
    R J Fontana
    Department of Internal Medicine, Consortium for Health Outcomes Innovation and Cost-Effectiveness Studies University of Michigan Medical School, Huron Gastroenterology Associates, Ann Arbor, USA
    Am J Gastroenterol 96:170-8. 2001
    ..Future studies that control for the presence of active comorbidities in large groups of treatment naive patients with varying severity of chronic HCV are needed to confirm these findings...
  32. ncbi Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry
    Cynthia Ko
    Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA
    Liver Int 27:1394-401. 2007
    ..This study examined the association between hepatic iron grade and hepatocellular carcinoma in patients with end-stage liver disease of diverse aetiologies...
  33. ncbi Management of patients with decompensated HBV cirrhosis
    Robert J Fontana
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, USA
    Semin Liver Dis 23:89-100. 2003
    ..Additional studies of individual or combination antiviral agents are urgently needed to improve further the prospects for the large number of patients worldwide with decompensated HBV cirrhosis...
  34. ncbi Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation
    S J Pelletier
    Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109-0331, USA
    Transplant Proc 37:1214-6. 2005
    ..However, the potential long-term benefits of steroid avoidance, including a decrease in severity of recurrent hepatitis C, remain under investigation...
  35. ncbi A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
    Chun-Tao Wai
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 38:518-26. 2003
    ..Application of this index may decrease the need for staging liver biopsy specimens among CHC patients...
  36. ncbi Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice
    Thomas M Shehab
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Clin Gastroenterol Hepatol 2:425-31. 2004
    ..In addition, our data show that medication adherence is an important predictor of SVR in an academic clinical practice...
  37. ncbi Characteristics of chronic hepatitis B patients who underwent liver biopsies
    W Chotiyaputta
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    J Viral Hepat 18:792-803. 2011
    ....
  38. ncbi Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States
    C-T Wai
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    J Viral Hepat 12:192-8. 2005
    ..Further studies are needed to determine if HBV genotypes play a role in the outcome of acute HBV infection...
  39. ncbi Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial
    R J Fontana
    University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 31:730-6. 2000
    ..Additional studies are needed to determine if iron reduction in combination with higher doses or longer duration of IFN may be of benefit...
  40. ncbi Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis
    L G Quallich
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    BMC Gastroenterol 1:8. 2001
    ..Although as many as 20% of treated patients may experience reversible, dose-dependent side effects, less frequent but potentially severe, systemic reactions have also been reported...
  41. ncbi Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Hepatology 44:925-35. 2006
    ..The excellent performance of the Virahep-C model in an external validation cohort suggests the findings are replicable and potentially generalizable...
  42. ncbi Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis
    Linas A Bieliauskas
    University of Michigan Medical Center, Ann Arbor, MI, USA
    J Clin Exp Neuropsychol 28:1346-61. 2006
    ..There was a significant correlation between cognitive impairment and self-reported depression...
  43. ncbi Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Hepatology 49:1828-37. 2009
    ..Decreased alcohol intake and improved metabolic parameters are associated with a decline in steatosis and may modulate hepatitis C progression...
  44. ncbi Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure
    William M Lee
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8887, USA
    Gastroenterology 137:856-64, 864.e1. 2009
    ..N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure...
  45. ncbi Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 136:138-48. 2009
    ..We evaluated the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort for the incidence of HCC and associated risk factors...
  46. ncbi An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data
    Shawn J Pelletier
    Division of Transplantation, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Liver Transpl 15:859-68. 2009
    ..The current criteria for liver transplantation of candidates with HCC lead to acceptable 5-year survival while limiting the dropout rate. Liver Transpl 15:859-868, 2009. (c) 2009 AASLD...
  47. ncbi Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    Hepatology 47:789-98. 2008
    ..The stronger correlation of the serum markers with Ishak scores suggests that serum fibrosis markers reflect the pattern of fibrosis more closely than the quantity of hepatic collagen...
  48. ncbi Renal outcomes after liver transplantation in the model for end-stage liver disease era
    Pratima Sharma
    Division of Gastroenterology, University of Michigan, Taubman Center, Ann Arbor, MI 48109, USA
    Liver Transpl 15:1142-8. 2009
    ..Further studies of modifiable preoperative, perioperative, and postoperative factors influencing renal function are needed to improve outcomes following LT...
  49. ncbi Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C
    Linas A Bieliauskas
    Neuropsychology Section, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
    J Int Neuropsychol Soc 13:687-92. 2007
    ..It is important to account for CRS when assessing cognitive findings in large-scale clinical trials...
  50. ncbi Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients
    Jorge A Marrero
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor 48109, USA
    Hepatology 37:1114-21. 2003
    ..810, respectively (P =.002). In conclusion, DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease. Prospective studies to evaluate the role of DCP in early HCC are underway...
  51. ncbi Emotional distress in chronic hepatitis C patients not receiving antiviral therapy
    Robert J Fontana
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 36:401-7. 2002
    ..The aim of our study was to determine the prevalence, type, and severity of emotional distress in a large group of consecutive chronic hepatitis C (CHC) patients not receiving anti-viral therapy...
  52. ncbi Acute liver failure due to amoxicillin and amoxicillin/clavulanate
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Dig Dis Sci 50:1785-90. 2005
    ..Early transfer of patients with severe drug-induced hepatotoxicity (i.e., encephalopathy or coagulopathy) to a transplant center is recommended due to their poor likelihood of recovery...
  53. ncbi Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy
    Robert J Fontana
    Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Gastroenterology 123:719-27. 2002
    ....
  54. ncbi Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 41:707-16. 2005
    ..The BCLC staging system includes aspects of all of these elements and provided the best prognostic stratification for our cohort of patients with HCC...
  55. ncbi Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 11:281-9. 2005
    ..If additional studies confirm our results, the noninvasive criteria utilized to make a diagnosis of HCC should be revised...
  56. ncbi Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 42:218-24. 2005
    ..The role of tobacco as a risk factor for HCC is controversial. Recently, obesity has been reported to be a risk factor for HCC. We investigated whether these factors increase the risk of HCC in American patients...
  57. ncbi NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States
    Jorge A Marrero
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 36:1349-54. 2002
    ..Because of the increasing incidence of NAFLD, further studies are needed to determine the risk of HCC in patients with NAFLD...
  58. ncbi Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond
    Robert J Fontana
    Department of Medicine, Division of Liver Transplantation, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Gastroenterol Clin North Am 33:527-47, viii. 2004
    ....
  59. ncbi Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Gastroenterol Hepatol 2:183-97. 2004
  60. ncbi Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Liver Transpl 8:1165-74. 2002
    ....
  61. ncbi Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:614-22. 2005
    ..The aim of this study was to determine the frequency, type, and severity of cognitive impairment in a large group of CHC patients with advanced fibrosis...
  62. ncbi Virologic response and resistance to adefovir in patients with chronic hepatitis B
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA
    J Hepatol 44:283-90. 2006
    ..The cumulative probability of adefovir resistance at 2 years was 22%. Our data suggest that combination of lamivudine and adefovir may prevent emergence of adefovir resistance in patients with lamivudine-resistant HBV...
  63. ncbi Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
    Jeong M Park
    College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
    Liver Transpl 12:112-6. 2006
    ..Additional prospective studies with close monitoring for CMV viremia and drug resistance are needed to further establish the optimal dose and duration of VGCV in liver transplant recipients...
  64. ncbi High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Clin Gastroenterol 34:177-82. 2002
    ..Kinetic studies have demonstrated a more rapid reduction in hepatitis C virus (HCV) RNA levels among patients taking high daily doses of interferon compared with those taking standard-dose interferon...
  65. ncbi Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs
    W Chotiyaputta
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
    J Viral Hepat 19:205-12. 2012
    ..Patients with chronic hepatitis B with better adherence to NUC therapy had a trend towards a lower rate of viral breakthroughs...
  66. ncbi An update on drug induced liver injury
    A S Rangnekar
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Minerva Gastroenterol Dietol 57:213-29. 2011
    ....
  67. ncbi Elevated troponin I levels in acute liver failure: is myocardial injury an integral part of acute liver failure?
    Nimisha K Parekh
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Hepatology 45:1489-95. 2007
    ..Measurement of troponin I levels may be helpful in patients with acute liver failure, to detect unrecognized myocardial damage and as a marker of unfavorable outcome...
  68. ncbi Noninvasive monitoring of patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, USA
    Hepatology 36:S57-64. 2002
    ..There is an urgent need to develop and validate noninvasive tests that can accurately reflect the full spectrum of hepatic inflammation and fibrosis in chronic hepatitis C...
  69. ncbi Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes
    Ryan M Taylor
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0362, USA
    Hepatology 44:1589-97. 2006
    ....
  70. ncbi Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study
    Shelly A McNeil
    Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA
    Clin Infect Dis 42:195-203. 2006
    ..Strategies should be implemented to reduce nosocomial VRE acquisition after transplantation among this vulnerable group...
  71. ncbi Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:374-81. 2007
    ..Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients...
  72. ncbi The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre
    A G Singal
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Aliment Pharmacol Ther 31:625-33. 2010
    ..The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined...
  73. ncbi Liver transplantation in acute liver failure
    P D R Higgins
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI, USA
    Panminerva Med 45:85-94. 2003
    ..In the meanwhile, it is recommended that acute liver failure patients be managed in experienced centers with ready access to liver transplantation to optimize outcomes in this rare but frequently fatal illness...
  74. ncbi Seropositive abdominal and thoracic donor organs are largely underutilized
    R M Taylor
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Transplant Proc 42:4479-87. 2010
    ..Both thoracic and abdominal organs from seropositive donors are largely underutilized...
  75. ncbi Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery
    John J Kim
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    J Clin Gastroenterol 43:574-9. 2009
    ..The aim of our study was to assess the clinical outcomes in consecutive cirrhotic patients with a patent TIPS undergoing major extrahepatic surgery...
  76. ncbi Management of drug-resistant chronic hepatitis B
    Scott K Fung
    Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Clin Liver Dis 10:275-302, viii. 2006
    ..Studies of pegylated interferon combined with an antiviral agent or dual nucleoside/nucleotide combination therapy are awaited to minimize the incidence of drug-resistant HBV and improve long-term outcomes...
  77. ncbi Clinical significance of hepatitis B virus genotypes, variants, and mutants
    Chun-Tao Wai
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
    Clin Liver Dis 8:321-52, vi. 2004
    ..The introduction of additional nucleoside/nucleotide analog agents will likely lead to the development of further unique polymerase mutants with varying pathogenicity and cross-resistance to existing drugs...
  78. ncbi Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study
    Anne M Larson
    Department of Internal Medicine, Division of Gastroenterology, University of Washington Medical Center, Seattle, 98195, USA
    Hepatology 42:1364-72. 2005
    ..Susceptible patients have concomitant depression, chronic pain, alcohol or narcotic use, and/or take several preparations simultaneously. Education of patients, physicians, and pharmacies to limit high-risk use settings is recommended...
  79. ncbi False positive acetaminophen concentrations in patients with liver injury
    Julie Polson
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5959 Harry Hines Boulevard, Dallas, TX 75390, USA
    Clin Chim Acta 391:24-30. 2008
    ..However, recent case reports have suggested that acetaminophen concentrations may be falsely increased in the presence of hyperbilirubinemia...
  80. ncbi IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis
    A S Rangnekar
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    J Viral Hepat 20:377-84. 2013
    ..In contrast, the favourable IL-28B genotype is associated with RVR, but not SVR in Asian HCV genotype 2 patients...
  81. ncbi Helicobacter pylori-associated gastric MALT lymphoma in liver transplant recipients
    T M Shehab
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109-0362, USA
    Transplantation 71:1172-5. 2001
    ....
  82. ncbi Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C
    K B Hussain
    Division of Gastroenterology, University of Michigan Health System, Ann Arbor 48109, USA
    Am J Gastroenterol 96:2737-44. 2001
    ..CHC alone is associated with significant impairment in HRQOL, but the presence of comorbid illness leads to further diminution in HRQOL...
  83. ncbi Acute hepatitis associated with alosetron (Lotronex)
    D Kim Turgeon
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    J Clin Gastroenterol 39:641-2. 2005
    ..Clinicians prescribing alosetron should be aware of this potential side effect if unexplained abdominal pain, jaundice,or abnormal liver biochemistries are encountered in a treated patient...
  84. ncbi Transjugular intrahepatic portosystemic shunts in liver transplant recipients
    John J Kim
    Department of Internal Medicine, 3912 Taubman Center, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Int 28:240-8. 2008
    ....
  85. ncbi Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury
    Kartik Jinjuvadia
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 102:2437-43. 2007
    ....
  86. ncbi Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature
    Ryan M Taylor
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA
    Liver Transpl 12:781-91. 2006
    ..Corticosteroids and immunoglobulin infusions were effective in 50% while the remainder of patients required rituximab infusions or eventual splenectomy for long-term disease remission...
  87. ncbi Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States
    George Ostapowicz
    Department of Medicine, Gold Coast Hospital, 108 Nerang Street, Southport, QLD 4215, Australia
    Ann Intern Med 137:947-54. 2002
    ..Apparent cause and coma grade at admission were associated with outcome. Although transplantation may improve patient survival, it was unavailable or unnecessary for most patients...
  88. ncbi Combination of HBIG and lamivudine-resistant mutations: a formula for trouble?
    Robert J Fontana
    Division of Gastroenterology University of Michigan Medical School Ann Arbor, MI, USA
    Liver Transpl 8:1082-4. 2002
  89. ncbi Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?
    Robert J Fontana
    Gastroenterology 130:1357-62. 2006
  90. ncbi A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis
    Hie Won L Hann
    Department of Medicine, Jefferson Medical College, 1025 Walnut Street Room 910, Philadelphia, PA 19107, USA
    Liver Transpl 9:49-56. 2003
    ..Additional studies of lamivudine in combination with other antivirals are indicated for the large population of patients worldwide with advanced HBV-related cirrhosis and inadequate access to liver transplantation...
  91. ncbi Renal transplantation in HBsAg+ patients: is lamivudine your "final answer"?
    Robert J Fontana
    J Clin Gastroenterol 37:9-11. 2003
  92. ncbi Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C
    Herbert L Bonkovsky
    Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
    Gastroenterology 131:1440-51. 2006
    ....
  93. ncbi Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
    Herbert L Bonkovsky
    Liver Biliary Pancreatic Center and the Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA
    J Hepatol 46:420-31. 2007
    ..This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial...
  94. ncbi Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy
    Javier Vaquero
    Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Liver Transpl 11:1581-9. 2005
    ..In view of the high 30-day survival rate after LT, future studies of the impact of intracranial hypertension should also focus on long-term neurological recovery from ALF...
  95. ncbi Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus
    Leland J Yee
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    Hepatology 46:74-83. 2007
    ..CONCLUSION: In addition to other factors, polymorphisms in cytokine genes may play a role in the progression of HCV-related fibrosis; however, further studies are needed...
  96. ncbi Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry
    Kris V Kowdley
    University of Washington, Seattle, 98195, USA
    Gastroenterology 129:494-503. 2005
    ..We examined the effect of HFE mutations on posttransplantation survival in patients with hepatic iron overload...
  97. ncbi Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests
    Jessica D Korman
    Montefiore Medical Center, Bronx, NY, USA
    Hepatology 48:1167-74. 2008
    ..More readily available laboratory tests including alkaline phosphatase, bilirubin and serum aminotransferases by contrast provides the most rapid and accurate method for diagnosis of ALF due to WD...
  98. ncbi Management of decompensated HBV cirrhosis: lamivudine and beyond
    Robert J Fontana
    Am J Gastroenterol 99:64-7. 2004
  99. ncbi "Unintentional" acetaminophen overdose on the rise: who is responsible? Dr Robert J Fontana is interviewed by Paul C Adams
    Robert J Fontana
    Can J Gastroenterol 20:319-24. 2006
  100. ncbi Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials
    Naga Chalasani
    Indiana University Medical Center, Indianapolis, USA
    Hepatology 41:289-98. 2005
    ..Randomized controlled studies are needed to establish the efficacy of pegylated interferon and ribavirin in patients who have undergone OLT...
  101. ncbi Curricular guidelines for training in transplant hepatology
    Hugo R Rosen
    Liver and Intra-Abdominal Subcommittee, American Society for Transplantation, USA
    Liver Transpl 8:85-7. 2002